Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Vancouver General Hospital · Wake Forest University · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,365
total citations
- FWCI
- 82.79
- Percentile
- 100%
- References
- 27
Citations per year
Authors
14- JMJ. Mark FitzGeraldCorresponding
Vancouver General Hospital
- EREugene R. Bleecker
Wake Forest University
- PNParameswaran Nair
St. Joseph’s Healthcare Hamilton, McMaster University
- SKStephanie Korn
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Johannes Gutenberg University Mainz
- KOKen Ohta
Tokyo National Hospital
Topics & keywords
Topics
Keywords
- Benralizumab
- Medicine
- Placebo
- Mepolizumab
- Asthma
- Exacerbation
- Internal medicine
- Clinical endpoint
No related works found for this paper.